Company intelligence / Profile preview

WestVac Biopharma

Chengdu, Sichuan, China

Ownership: Private
Development stage: Commercial

Overview

The recombinant protein-based COVID–19 vaccines have demonstrated satisfactory immunogenicity in early clinical trials. The trivalent XBB.1.5 subunit protein-based candidate is positioned as a next-generation broad-spectrum booster against emerging variants and has advanced to late-stage clinical development internationally, with approval for use in China since December 2022.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Recombinant protein vaccines (insect cell expression)mRNA vaccinesBacterial vaccinesTumor/immunotherapy platforms
Industry: Biotech

Drug pipeline

21 assets

recombinant COVID-19 (XBB) trimer protein vaccine

20 more assets in the full pipeline.

Request access →

Partnerships

WHOBill & Melinda Gates FoundationPATHCEPIEuropean Vaccine InitiativeNagasaki University for Japan trial

Beyond the preview

Go deeper on WestVac Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WestVac Biopharma.

Explore the full profile